BUZZ-Novonesis climbs on 2025 guidance, buy-back

Shares in Novonesis NSISb.CO climb 5% after the Danish biotechnology company reported 2025 guidance for adjusted EBITDA in line with expectations, announced EUR 100 million ($105.05 million) share buy-back

J.P.Morgan says that the in-line guidance should reassure investors, given concerns on the growth outlook for the financial year 2025

JPM adds that the company's H2 pro forma special items of about EUR 70 million and PPA amortisation of about EUR 164 million were ahead of expectations, resulting in EBIT and reported net profit below estimates

JPM also notes the "very strong" H2 adjusted gross margin which is at 58%, compared to 56% consensus

For 2025 the adjusted EBITDA margin is guided at 37-38%, which is "close to consensus," says JPM

The stock is among the top performers on the Copenhagen 20 .OMXC20 index

($1 = 0.9519 euros)